• Vaccine Name: Pvs25-IMX313/Matrix-M1
• Target Pathogen: Plasmodium spp.
• Target Disease: Malaria
• Type: Subunit vaccine
• Status: Clinical trial
• Host Species for Licensed Use: Human
• Antigen: Pvs25 (Minassian et al., 2022): P.vivax surface protein 25, composed of four cysteine-rich epidermal growth factor–like domains expressed on the surface of zygotes and ookinetes of P. vivax (Arevalo-Herrera et al., 2005).
• Pvs25 gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant: Matrix-M(Minassian et al., 2022): activate and recruit immune cells to the draining lymph node (Mulamba et al., 2022); IMX313(Minassian et al., 2022): a hybrid of the oligomerization domain of chicken complement inhibitor C4-binding protein (C4bp), 21% homology to the sequence of the human protein. Pvs25 antigen fused to IMX313 oligomerization domain (Mulamba et al., 2022).
• Immunization Route: Intramuscular injection (i.m.)

Human Response

• Host Strain: healthy adults in United Kingdom (Minassian et al., 2022)
• Vaccination Protocol: Non-randomised, Phase Ia study, not started
  Volunteers will receive 1) three doses of 10 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56, 2) three doses of 50 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56, or 3) two doses of 50 µg Pvs25-IMX313 in 50 µg Matrix-M1 on days 0 and 28, followed by one dose of 10 µg Pvs25-IMX313 in 50 µg Matrix-M1 on day 56 (Minassian et al., 2022)